

FUNCTIONAL PRECISION MEDICINE IN BLOOD CANCER

25-26TH MARCH, 2021

VIRTUAL MEETING

PROGRAM COMMITTEE

Jean-Pierre Bourquin, Zürich

Caroline Heckman, Helsinki

Uli Jäger, Vienna

Markus Manz, Zürich

Kimmo Porkka, Helsinki

Berend Snijder, Zürich

Philipp Staber, Vienna

Gulio Superti-Furga, Vienna

Gregory Vladimer, Vienna

Krister Wennerberg, Copenhagen

Thorsten Zenz, Zürich

Sponsors (MIT LOGOS)

PLATINUM: Abbvie

GOLD: Roche, Novartis

SILVER: Takeda, Gilead, Janssen, Celgene, Amgen Logo

BRONZE: AstraZeneca, Allcyte, Karyopharm



DEAR COLLEAGUES,

We cordially invite you to the **2021 Functional Precision Medicine in Blood Cancer Symposium** that will be hosted in the context of a *European Functional Precision Medicine Initiative* in cooperation with the *EHA-SWG Functional Precision Hematology*, and the *Society for Functional Precision Medicine*.

The symposium will take place **March 25-26th, 2021 – virtual** - and will bring together global experts on high-throughput drug screening, precision medicine and blood cancer.

We are looking forward to welcome you at the 2021 Functional Precision Medicine in Blood Cancer Symposium.

The local Organizing Committee:

Jean-Pierre Bourquin
Childrens` University
Hospital Zürich

Thorsten Zenz
University Hospital Zurich

Berend Snijder
ETH Zurich

EHA LOGO

CRPP Precision Hematology / Oncology, UZH

MARCH 25th

- 12:00 - 12:15 **Welcome** – *T. Zenz, A.G. Letai*
- 12:15 - 12:40 **Keynote Lecture: Targeting Cell Death in Leukemia** – *A. Roberts*
- 12:45 - 14:05 **Advantages in Platform Technology** - *B. Bornhauser, K. Wennerberg*
- 12:45 - 13:00 Single Cell Proteomics - *B. Becher*
- 13:05 - 13:20 Systems level analysis of tumor ecosystems by imaging mass cytometry enables precision medicine- *B. Bodenmiller*
- 13:25 - 13:40 Multiplexed Image-based Screening – *B. Snijder*
- 13:45 - 14:00 Ex Vivo Drug Testing for Enhancers of CART Cytotoxicity – *S. Mustjoki*
- 14:05 - 15:00 **Break**
- 15:00 - 16:00 **Functional Precision Medicine** - *M. Manz, J.P. Bourquin*
- 15:00 - 15:20 Need for Precision Medicine in AML - *B. Löwenberg*
- 15:20 - 15:40 Need for Precision Medicine in Lymphoma - *L. Staudt*
- 15:45 - 16:00 Need for Precision Medicine in Childhood Leukemia – *K. Stegmaier*
- 16:00 - 16:30 **Break**
- 17:30 - 17:45 **Functional Genomics to identify new vulnerabilities** – *A. Puissant*
- 17:50 - 18:30 **Precision Hematology & Associated Data Science I**
- 17:55 - 18:10 **Topic (t.b.c.)** - *P. Horvath*
- 18:15 - 18:30 **Topic (t.b.c.)** - *K. Tasken*

MARCH 26th

- 12:00 - 13:20 **Lymphoma** - *U. Jäger, T. Zenz*
- 12:00 - 12:15 Clinical Impact of Multi-Drug Testing in Lymphoma – *T. Pemovska*
- 12:20 - 12:35 Functional Precision Medicine in Lymphoma - *S. Dietrich*
- 12:40 - 12:55 Guiding treatment of blood cancers with BH3 profiling- *A. Letai*
- 13:00 - 13:15 Predictive Biomarker Discovery for Ibrutinib plus Venetoclax Treatment of CLL – *S. Skånland*
- 13:20 - 14:00 **Break**
- 14:00 - 15:00 **Acute Leukemia** – *C. Heckman, K. Porkka*
- 14:00 - 14:15 Functional Precision Medicine in Childhood Leukemia - *J.P. Bourquin*
- 14:20 - 14:35 FACS-based drug profiling in AML - *R. Itzykson*
- 14:40 - 14:55 Patient-centric Translational Research using High Content Microscopy and Deep Learning - *G. Vladimer*
- 15:00 - 15:30 **Break**
- 15:30 - 16:50 **Precision Hematology & Associated Data Science II**
- 15:30 - 15:45 Multi-Omics Factor Analysis - *W. Huber*
- 15:50 - 16:05 Prediction of combinatorial effects - *T. Aittokallio*
- 16:05 - 17:00 **Break**
- 17:00 - 18:20 **Clinical Translation of FPM**
- 17:00 - 17:15 Functional Precision Medicine in Adult Leukemia: Clinical Translation - *K. Porkka*
- 17:20 - 17:35 Beat AML Lymphoma - *J. Tyner*
- 17:40 - 17:55 EXALT, using functional assays to instruct treatment in advanced hem cancers - *P. Staber*
- 18:00 - 18:15 Lymphoid malignancies - *T. Zenz*
- ...

INFORMATION

SPEAKERS & CHAIRS

Bernd Bodenmiller, University of Zurich, Switzerland
Beat Bornhauser, Childrens` University Hospital Zürich, Switzerland
Jean-Pierre. Bourquin, Childrens` University Hospital Zurich, Switzerland
Renaud Capdeville, Novartis, Switzerland
Sascha Dietrich, University Hospital Heidelberg, Germany
Caroline Heckmann, University of Helsinki, Finland
Uli Jäger, Medical University Vienna, Austria
Olli Kallioniemi, Karolinska Institutet, Sweden
Anthony G. Letai, Dana-Farber Cancer Institute, United States of America
Bob Löwenberg, Erasmus University Medical Center, Netherlands
Gerd Maass, Roche, Switzerland
Markus Manz, University Hospital Zurich, Switzerland
Celine Pallaud, Novartis, Switzerland
Kimmo Porkka, University of Helsinki, Finland
Sigrid Skånland, Oslo University Hospital, Norway
Berend Snijder, Swiss Federal Institute of Technology (ETH) Zurich, Switzerland
Philipp Staber, University Hospital Vienna, Austria
Jeffrey Tyner, Knight Cancer Research Building, OHSU, United States of America
Gregory Vladimer, Allcyte, Austria
Krister Wennerberg, Biotech Research & Innovation Centre, Denmark
Thorsten Zenz, University Hospital Zurich, Switzerland
Andrew Roberts, Royal Melbourne Hospital, Australia
Burkhard Becher, University of Zurich, Switzerland
Satu Mustjoki, University of Helsinki, Finland

Louis M. Staudt, National Cancer Institute, United States of America
18:20 - 18:30 Virtual Break

18:30 - 19:30 Round Table on Opportunities and Challenges of translating FPM in clinical care (JP Bourquin, T Zenz, K. Porkka)

Renaud Capdeville, Novartis, CH
Celine Pallaud, Novartis, CH
Gerd Maas, Roche, CH (t.b.c.)
Ulrich Jäger, Medical University Vienna
Markus Manz, University Hospital Zurich (t.b.c.)
Bob Löwenberg, Erasmus University Medical Center, Rotterdam
Olli Kallioniemi, Karolinska Institutet, Stockholm (t.b.c.)
Jeffrey Tyner, Knight Cancer Research Building, OHSU, Portland
Gulio Superti-Furga, Vienna (t.b.c.)

Kimberly Stegmaier, Boston Children´s Hospital, United States of America
Alexandre Puissant, Saint-Louis Hospital Paris, France
Tea Pemovska, Medical University Vienna, Austria
Raphael Itzykson, Saint-Louis Hospital, France
Tero Aittokallio, Institute of Cancer Research Oslo, Norway
Wolfgang Huber, EMBL, Germany
Kjetil Tasken, Oslo University Hospital, Norway
Peter Horvath, Szeged, Hungary

ORGANIZATION

Childrens` University Hospital Zürich
University Hospital Zurich (USZ)
Eidgenössische Technische Hochschule (ETH) Zurich
C3Z – Comprehensive Cancer Center Zürich
Contact: Jean-Pierre.Bourquin@kispi.uzh.ch

REGISTRATION

Registration is mandatory. The registration fee for profit organizations is CHF 250,00.

<http://www.cancercenter.usz.ch/ueber-das-zentrum/events/aerzte-wissenschaftler/Seiten/registration-functional-precision-medicine-in-blood-cancer-symposium.aspx>



